EMCDDA — the first 25 years 30.01.2020
This year, the EMCDDA celebrates 25 years of monitoring the drug situation in Europe. In the quarter of a century since the agency embarked on its first work programme in 1995, we have seen revolutionary changes, both in the extent and nature of the drugs problem, and in the world in which we live. Keeping pace with an increasingly dynamic drug phenomenon, while remaining relevant to policy and practice, requires constant reflection, innovation and agility.
Čtěte více
EMCDDA Director Alexis Goosdeel was at the European Parliament today, where he presented the findings of the EMCDDA–Europol EU Drug Markets Report 2019 (EDMR 2019) to the Committee on Civil Liberties, Justice and Home Affairs (LIBE). 28.01.2020
Čtěte více
EMCDDA Director Alexis Goosdeel is in Washington today where he will meet Ambassador Adam Namm, Executive Secretary of the Inter-American Drug Abuse Control Commission (CICAD). The purpose of the visit is to discuss ongoing EMCDDA–CICAD cooperation and review the topics to be addressed under the joint work programme (2020–2024). Respectively, the two organisations lead the regional drug information systems of Europe and the Americas and, in so doing, make a valuable contribution to evidence-based information on drugs at global level. 21.01.2020
Čtěte více
From 16 December 2019, edible cannabis products are permitted to be sold in Canada. These must comply with new regulations for edible, inhalable and topical products, designed to reduce the risk of accidental consumption or overconsumption. Edible products are not individually approved for sale, but the regulations instruct manufacturers to provide Health Canada with a written notice of the product – including class of product, description and expected date of offering for sale – then wait 60 days before sale, to give the authorities time to raise any concerns. 20.01.2020
Čtěte více
